Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11 - 30; http://dx.doi.org/10.3322/caac.21166; PMID: 23335087
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666 - 75; PMID: 11157016
   PubMed Web of Science ®Google Scholar
• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239 - 49; http://dx.doi.org/10.1016/S0140-6736(09)60491-8; PMID: 19520422
   PubMed Web of Science ®Google Scholar
• Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010; 28:401 - 8; http://dx.doi.org/10.1016/j.urolonc.2009.04.019; PMID: 20610278
   PubMed Web of Science ®Google Scholar
• Resnick MJ, Bassett JC, Clark PE. Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr Opin Oncol 2013; 25:281 - 8; PMID: 23425709
   PubMed Web of Science ®Google Scholar
• Volpe A, Racioppi M, D’Agostino D, D’Addessi A, Marangi F, Totaro A, Pinto F, Sacco E, Battaglia S, Chiloiro G, et al. Advanced bladder cancer: new agents and new approaches. A review. Urol Oncol 2013; 31:9 - 16; http://dx.doi.org/10.1016/j.urolonc.2010.03.022; PMID: 20864362
   PubMed Web of Science ®Google Scholar
• Tsai YC, Yeh CH, Tzen KY, Ho PY, Tuan TF, Pu YS, Cheng AL, Cheng JC. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer 2013; 49:1458 - 66; http://dx.doi.org/10.1016/j.ejca.2012.10.020; PMID: 23153706
   PubMed Web of Science ®Google Scholar
• Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011; 17:5935 - 44; http://dx.doi.org/10.1158/1078-0432.CCR-11-0370; PMID: 21791633
   PubMed Web of Science ®Google Scholar
• Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009; 8:94; http://dx.doi.org/10.1186/1476-4598-8-94; PMID: 19878607
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3:224 - 37; http://dx.doi.org/10.1158/2159-8290.CD-12-0349; PMID: 23220880
   PubMed Web of Science ®Google Scholar
• Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 2012; 61:810 - 7; http://dx.doi.org/10.1016/j.eururo.2012.01.017; PMID: 22277196
   PubMed Web of Science ®Google Scholar
• Alexa A, Baderca F, Zăhoi DE, Lighezan R, Izvernariu D, Raica M. Clinical significance of Her2/neu overexpression in urothelial carcinomas. Rom J Morphol Embryol 2010; 51:277 - 82; PMID: 20495743
   PubMed Web of Science ®Google Scholar
• Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010; 106:1216 - 22; http://dx.doi.org/10.1111/j.1464-410X.2009.09190.x; PMID: 20089105
   PubMed Web of Science ®Google Scholar
• Junttila TT, Laato M, Vahlberg T, Söderström KO, Visakorpi T, Isola J, Elenius K. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003; 9:5346 - 57; PMID: 14614020
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46:Suppl S85 - 104; http://dx.doi.org/10.1016/S1040-8428(03)00067-2; PMID: 12850530
   PubMedGoogle Scholar
• McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK, Kriajevska M. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 2009; 34:1155 - 63; PMID: 19287975
   PubMed Web of Science ®Google Scholar
• Bian L, Wang T, Zhang SH, Zhang HQ, Guo YF, Du G, Li W, Wu SK, Song ST, Jiang ZF. Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab. Cancer Biol Ther 2014; 15:365 - 70; http://dx.doi.org/10.4161/cbt.27624; PMID: 24424115
   PubMed Web of Science ®Google Scholar
• Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther 2012; 13:1501 - 11; http://dx.doi.org/10.4161/cbt.22275; PMID: 22990204
   PubMed Web of Science ®Google Scholar
• Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011; 11:793 - 800; http://dx.doi.org/10.4161/cbt.11.9.15045; PMID: 21307659
   PubMed Web of Science ®Google Scholar
• McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. Urology 2007; 69:390 - 4; http://dx.doi.org/10.1016/j.urology.2006.12.003; PMID: 17320695
   PubMed Web of Science ®Google Scholar
• Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F, El-Hariry IA. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115:2881 - 90; http://dx.doi.org/10.1002/cncr.24337; PMID: 19399906
   PubMed Web of Science ®Google Scholar
• Halterman PA. Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Pharmacotherapy 2008; 28:1255 - 66; http://dx.doi.org/10.1592/phco.28.10.1255; PMID: 18823221
   PubMed Web of Science ®Google Scholar
• Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43:875 - 8; http://dx.doi.org/10.1038/ng.907; PMID: 21822268
   PubMed Web of Science ®Google Scholar
• Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44:195 - 217; http://dx.doi.org/10.1146/annurev.pharmtox.44.101802.121440; PMID: 14744244
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341 - 54; http://dx.doi.org/10.1038/nrc1609; PMID: 15864276
   PubMed Web of Science ®Google Scholar
• COSMIC. Wellcome Trust Sanger Institute: Catalogue of somatic mutations in cancer (COSMIC). Wellcome Trust Sanger Institute, 2013.
   Google Scholar
• Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 2012; 109:14476 - 81; http://dx.doi.org/10.1073/pnas.1203201109; PMID: 22908275
   PubMed Web of Science ®Google Scholar
• Finger C, Escher C, Schneider D. The single transmembrane domains of human receptor tyrosine kinases encode self-interactions. Sci Signal 2009; 2:ra56; http://dx.doi.org/10.1126/scisignal.2000547; PMID: 19797273
   PubMed Web of Science ®Google Scholar
• Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A 2002; 99:15937 - 40; http://dx.doi.org/10.1073/pnas.252640799; PMID: 12461170
   PubMed Web of Science ®Google Scholar
• Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 2001; 311:1011 - 26; http://dx.doi.org/10.1006/jmbi.2001.4923; PMID: 11531336
   PubMed Web of Science ®Google Scholar
• Bargmann CI, Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988; 7:2043 - 52; PMID: 2901345
   PubMed Web of Science ®Google Scholar
• Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97:729 - 36; http://dx.doi.org/10.1182/blood.V97.3.729; PMID: 11157491
   PubMed Web of Science ®Google Scholar
• d’Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 1998; 9:71 - 8; PMID: 9438390
   PubMedGoogle Scholar
• Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10:25 - 38; http://dx.doi.org/10.1016/j.ccr.2006.05.023; PMID: 16843263
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871 - 90; http://dx.doi.org/10.1016/j.cell.2009.11.007; PMID: 19945376
   PubMed Web of Science ®Google Scholar
• Gunes S, Sullu Y, Yegin Z, Buyukalpelli R, Tomak L, Bagci H. ErbB receptor tyrosine kinase family expression levels in urothelial bladder carcinoma. Pathol Res Pract 2013; 209:99 - 104; http://dx.doi.org/10.1016/j.prp.2012.10.014; PMID: 23333248
   PubMed Web of Science ®Google Scholar
• Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol 2014; 27:758 - 64; http://dx.doi.org/10.1038/modpathol.2013.201; PMID: 24186136
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129 - 39; http://dx.doi.org/10.1056/NEJMoa040938; PMID: 15118073
   PubMed Web of Science ®Google Scholar
• Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, et al. KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies. Lung Cancer 2014; 83:163 - 7;; http://dx.doi.org/10.1016/j.lungcan.2013.11.010; PMID: 24331409
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010; 28:4769 - 77; http://dx.doi.org/10.1200/JCO.2009.27.4365; PMID: 20921461
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014; 33:2949 - 55; http://dx.doi.org/10.1038/onc.2013.244; PMID: 23792451
   PubMed Web of Science ®Google Scholar
• Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 2011; 11:81 - 92; http://dx.doi.org/10.1038/tpj.2010.81; PMID: 20975737
   PubMed Web of Science ®Google Scholar
• Guo Y, Chekaluk Y, Zhang J, Du J, Gray NS, Wu CL, Kwiatkowski DJ. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol 2013; 230:17 - 27; http://dx.doi.org/10.1002/path.4176; PMID: 23401075
   PubMed Web of Science ®Google Scholar
• Herter-Sprie GS, Greulich H, Wong KK. Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol 2013; 3:86; http://dx.doi.org/10.3389/fonc.2013.00086; PMID: 23630663
   PubMedGoogle Scholar
• Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28:511 - 5; http://dx.doi.org/10.1038/nbt.1621; PMID: 20436464
   PubMed Web of Science ®Google Scholar
• De Hoon MJ, Imoto S, Miyano S. Statistical analysis of a small set of time-ordered gene expression data using linear splines. Bioinformatics 2002; 18:1477 - 85; http://dx.doi.org/10.1093/bioinformatics/18.11.1477; PMID: 12424119
   PubMed Web of Science ®Google Scholar
• de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004; 20:1453 - 4; http://dx.doi.org/10.1093/bioinformatics/bth078; PMID: 14871861
   PubMed Web of Science ®Google Scholar
• Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44 - 57; http://dx.doi.org/10.1038/nprot.2008.211; PMID: 19131956
   PubMed Web of Science ®Google Scholar
• Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37:1 - 13; http://dx.doi.org/10.1093/nar/gkn923; PMID: 19033363
   PubMed Web of Science ®Google Scholar